| Not Yet Recruiting | Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pa NCT06897917 | Henan Cancer Hospital | Phase 4 |
| Completed | Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications NCT05133076 | BioGaia Pharma AB | Phase 2 |
| Completed | European Study of Opioid Induced Constipation NCT05149833 | University of Dublin, Trinity College | — |
| Recruiting | Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipatio NCT03720613 | BioDelivery Sciences International | — |
| Completed | Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC. NCT03638440 | Kyowa Kirin Pharmaceutical Development Ltd | — |
| Completed | Colonic Motor Patterns in Healthy Volunteers NCT05770960 | Universitaire Ziekenhuizen KU Leuven | Phase 4 |
| Completed | Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol NCT04173858 | Kyowa Kirin Farmacéutica S.L.U. | — |
| Completed | Study of Opioid-Induced Constipation 2 Project NCT04404933 | Royal Surrey County Hospital NHS Foundation Trust | — |
| Completed | Study of Opioid-Induced Constipation 1 Project NCT04350112 | Royal Surrey County Hospital NHS Foundation Trust | — |
| Unknown | Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation NCT03687268 | Develco Pharma Schweiz AG | Phase 3 |
| Completed | To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation NCT03060512 | AstraZeneca | Phase 4 |
| Terminated | Naloxegol Health Outcome Post Authorisation Safety Study NCT02813369 | Kyowa Kirin Pharmaceutical Development Ltd | — |
| Unknown | Naloxegol US PMR CV Safety. NCT02813356 | Valinor Pharma LLC | — |
| Completed | Naloxegol Drug Utilization Post Authorisation Safety Study NCT02813148 | Kyowa Kirin Pharmaceutical Development Ltd | — |
| Unknown | Study of Methylnaltrexone in Opioid-Induced Constipation Patients NCT02574819 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 / Phase 3 |
| Completed | Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Pati NCT02270983 | Forest Laboratories | Phase 2 |
| Completed | Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation NCT01993940 | Shionogi | Phase 3 |
| Completed | A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Rever NCT01957046 | Mundipharma Research GmbH & Co KG | Phase 4 |
| Completed | Long Term Safety of Naldemedine NCT01965652 | Shionogi | Phase 3 |
| Completed | Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation NCT01965158 | Shionogi | Phase 3 |
| Terminated | The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation NCT01901341 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Completed | Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives NCT01812733 | Mundipharma AB | — |
| Terminated | Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation NCT01901302 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Terminated | Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation NCT01901328 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Terminated | Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation NCT01696643 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Completed | Assessing a Stool Symptom Screener in Patients With Chronic Opioid-Induced Constipation NCT01645371 | AstraZeneca | — |
| Completed | Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol NCT01623609 | AstraZeneca | Phase 1 |
| Completed | A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1 NCT01459926 | Theravance Biopharma | Phase 2 |
| Completed | A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC) NCT01401985 | Theravance Biopharma | Phase 2 |
| Completed | A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignan NCT01443403 | Shionogi | Phase 2 |
| Completed | ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC) NCT01382797 | Alkermes, Inc. | Phase 2 |
| Terminated | Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pai NCT01384292 | AstraZeneca | Phase 3 |
| Completed | Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Ta NCT01207427 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants NCT01186770 | Bausch Health Americas, Inc. | Phase 3 |
| Terminated | Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation NCT01117051 | Shire | Phase 3 |
| Completed | ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC) NCT01100151 | Alkermes, Inc. | Phase 2 |
| Completed | A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy NCT01109511 | Ullevaal University Hospital | Phase 4 |
| Completed | A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation NCT01040637 | Theravance Biopharma | Phase 1 / Phase 2 |
| Unknown | Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit NCT01050595 | St. John Health System, Michigan | Phase 3 |
| Completed | Naloxone SR Capsules in Patients With Opioid Induced Constipation NCT00984334 | S.L.A. Pharma AG | Phase 2 |
| Withdrawn | Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer S NCT00858754 | Bausch Health Americas, Inc. | Phase 4 |
| Completed | Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness NCT00672139 | Bausch Health Americas, Inc. | Phase 4 |
| Completed | Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With A NCT00672477 | Bausch Health Americas, Inc. | Phase 4 |
| Completed | Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilit NCT00640146 | Bausch Health Americas, Inc. | Phase 2 |
| Terminated | Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. NCT00414024 | Novartis | Phase 3 |
| Terminated | Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. NCT00399659 | Novartis | Phase 3 |
| Completed | Compassionate Use Study of Methylnaltrexone NCT01368562 | Bausch Health Americas, Inc. | N/A |